{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T01:24:51Z","timestamp":1651454691079},"reference-count":6,"publisher":"FapUNIFESP (SciELO)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sao Paulo Med. J."],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:p>CONTEXT: Splenic marginal zone lymphoma (SMZL) is a lymphoproliferative B-cell disorder that has a favorable prognosis, with estimated overall five-year survival of 70%. The majority of symptomatic patients undergo splenectomy, while a few receive first-line chemotherapy, especially with purine analogues. There are no specific treatment guidelines for patients for whom splenectomy fails to provide a cure. It is still unclear whether these patients should undergo cytotoxic chemotherapy, considering they have now a relapsed lymphoma (which is theoretically more aggressive), or whether they should be spared from treatments of greater toxicity, given that their disease usually develops with a more indolent course, even when it recurs. CASE REPORT: Here, we present two patients whose disease recurred after splenectomy and for whom rituximab monotherapy provided satisfactory treatment. From these cases, it can be suggested that postponement of cytotoxic treatments may be possible in at least some situations. It needs to be emphasized that the evidence to support this approach is based only on case reports, since there are no randomized clinical trials on this subject.<\/jats:p>","DOI":"10.1590\/s1516-31802010000600012","type":"journal-article","created":{"date-parts":[[2011,4,16]],"date-time":"2011-04-16T05:31:35Z","timestamp":1302931895000},"page":"375-377","source":"Crossref","is-referenced-by-count":2,"title":["Rituximab monotherapy for splenic marginal zone lymphoma with villous lymphocytes: report on long-term disease control for two patients with recurrence after splenectomy"],"prefix":"10.1590","volume":"128","author":[{"given":"M\u00e1rcio","family":"Debiasi","sequence":"first","affiliation":[{"name":"PUCRS,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marluce","family":"Hehnemann","sequence":"additional","affiliation":[{"name":"PUCRS,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo","family":"Garicochea","sequence":"additional","affiliation":[{"name":"PUCRS,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"issue":"2","key":"ref1","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2141.1991.tb04417.x","article-title":"Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases","volume":"78","author":"Mulligan SP","year":"1991","journal-title":"Br J Haematol."},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cncr.21931","article-title":"Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone","volume":"107","author":"Tsimberidou AM","year":"2006","journal-title":"Cancer","ISSN":"http:\/\/id.crossref.org\/issn\/0008-543X","issn-type":"print"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/hon.844","article-title":"Re: Rituximab monotherapy is highly effective in splenic marginal zone lymphoma","volume":"26","author":"Bennett M","year":"2008","journal-title":"Hematol Oncol."},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/hon.820","article-title":"Rituximab monotherapy is highly effective in splenic marginal zone lymphoma","volume":"25","author":"Kalpadakis C","year":"2007","journal-title":"Hematol Oncol."},{"issue":"6","key":"ref5","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3816\/CLM.2006.n.033","article-title":"Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia","volume":"6","author":"Fabbri A","year":"2006","journal-title":"Clin Lymphoma Myeloma."},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.seminhematol.2010.01.004","article-title":"Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab","volume":"47","author":"Bennett M","year":"2010","journal-title":"Semin Hematol."}],"container-title":["Sao Paulo Medical Journal"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/spmj\/v128n6\/a12v1286.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T19:21:14Z","timestamp":1495826474000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1516-31802010000600012&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":6,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S1516-31802010000600012"],"URL":"https:\/\/doi.org\/10.1590\/s1516-31802010000600012","relation":{},"ISSN":["1516-3180"],"issn-type":[{"value":"1516-3180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}